SRF617

DRUG2 trials

Sponsors

Coherus Oncology, Inc.

Conditions

Advanced Solid TumorMetastatic Castration-resistant Prostate CancerProstate Cancer

Phase 1

Study of SRF617 in Patients With Advanced Solid Tumors

CompletedNCT04336098

Coherus Oncology, Inc.Advanced Solid Tumor

Start: 2020-03-16End: 2023-08-25Updated: 2024-06-04

Phase 2

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

TerminatedNCT05177770

Coherus Oncology, Inc.Metastatic Castration-resistant Prostate Cancer, Prostate Cancer

Start: 2022-01-17End: 2023-04-05Updated: 2025-05-08

Related Papers

247 The fully human antibody SRF617 is a potent inhibitor of ecto-enzyme CD39 in vivo

Regular and Young Investigator Award Abstracts2021-11-011 citations